Dospívající dívky vyhledávají gynekologa nejčastěji při poruchách menstruačního cyklu. V ideálním případě by se dívka měla obracet na dětského gynekologa, který ovšem není všude dostupný. Proto často řeší tento problém gynekologové specializovaní na dospělé pacientky. Ti většinou problém řeší předepsáním hormonální antikoncepce, jejíž podávání cyklus upraví. To však není kauzální řešení problému tzv. juvenilní metroragie. Její řešení patří do rukou dětského gynekologa, a pokud je nucen tento problém řešit gynekolog dospělých, měl by mu tento článek poskytnout základní informace., Adolescent girls most frequently seek a gynecologist’s advice in relation to menstrual cycle disorders. Ideally, they should visit a pediatric gynecologist, whose care, however, is not always within easy reach. Therefore this problem is often treated by gynecologists specialized in adult patients. In most cases they deal with it by prescribing hormonal contraception, whose administering will regulate the cycle. However this is not a causal solution of the issue of juvenile metrorrhagia. Its solution should be in the hands of pediatric gynecologists, and if gynecologists treating adults have to deal with this problem, this paper should give them some basic information., and Hana Kosová
Still's disease is an inflammatory disorder of unknown etiology. First-line therapy is based on corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) but the frequency of relapses and corticosteroid-induced adverse events are limiting factors. The efficacy of intravenous tocilizumab (TCZ) has been shown at a dose of 8 mg/kg but the corticosteroid-sparing effect of intravenous low-dose TCZ followed by subcutaneous (SC) injection in the course of the disease has been poorly investigated. We report the case of a 28-year old Caucasian woman presenting a relapse of Still's disease eleven months after diagnosis under treatment with 6 mg of methylprednisolone. TCZ at a dose of 4 mg/kg every 2 weeks was combined with 32 mg of methylprednisolone, followed by 162 mg SC every 3 weeks. Evolution was rapidly favourable with a decrease in corticosteroid doses. We reviewed previously published cases. and X. Vandemergel, F. Vandergheynst